Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

Arvinas, Inc.

Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and “undruggable” targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com.Community Guidelines: http://bit.ly/ArvinasCG

	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	6.67M -	7.58M 13.64%	14.32M 89.00%	42.98M 200.03%	21.80M 49.27%	46.70M 114.20%	131.40M 181.37%	78.50M 40.26%
cost of revenue								6.70M -
gross profit	6.67M -	7.58M 13.64%	14.32M 89.00%	42.98M 200.03%	21.80M 49.27%	46.70M 114.20%	131.40M 181.37%	71.80M 45.36%
selling and marketing expenses								-6.70M -
general and administrative expenses	3.20M -	3.55M 10.95%	12.93M 264.67%	27.31M 111.16%	38.30M 40.27%	61.60M 60.82%	79.60M 29.22%	100.30M 26.01%
selling general and administrative expenses	3.20M -	3.55M 10.95%	12.93M 264.67%	27.31M 111.16%	38.30M 40.27%	61.60M 60.82%	79.60M 29.22%	93.60M 17.59%
research and development expenses	19.94M -	28.79M 44.38%	45.19M 56.96%	67.19M 48.68%	108.36M 61.26%	180.40M 66.49%	315M 74.61%	379.70M 20.54%
other expenses	1.66M -	554.16K 66.54%	102.73K 81.46%	1.44M 1,297.45%	2.00M 39.63%	2.50M 24.72%	200K 92%	-1.20M 700%
cost and expenses	23.14M -	32.34M 39.76%	58.13M 79.74%	94.50M 62.58%	146.66M 55.19%	242M 65.01%	394.60M 63.06%	480M 21.64%
operating expenses	23.14M -	32.34M 39.76%	58.13M 79.74%	94.50M 62.58%	146.66M 55.19%	242M 65.01%	394.60M 63.06%	473.30M 19.94%
interest expense	67.40K -	50.36K 25.29%	57.44K 14.07%	85.57K 48.97%	65K 24.04%	100K 53.85%	12M 11,900%
ebitda	-13.95M -	-23.66M 69.60%	-43.80M 85.15%	-51.52M 17.63%	-124.86M 142.33%	-195.30M 56.42%	-263.20M 34.77%	-394.80M 50%
operating income	-16.47M -	-24.76M 50.34%	-43.80M 76.90%	-51.52M 17.63%	-124.86M 142.33%	-195.30M 56.42%	-263.20M 34.77%	-401.50M 52.55%
depreciation and amortization	436.33K -	347.39K 20.38%	706K 103.23%	2.25M 219.11%	4.02M 78.64%	6M 49.09%	8.20M 36.67%	6.70M 18.29%
total other income expenses net	1.67M -	560.03K 66.49%	-91.05K 116.26%	-18.77M 20,512.76%	5.53M 129.44%	4.30M 22.18%	12.20M 183.72%	37.60M 208.20%
income before tax	-14.44M -	-24.05M 66.57%	-41.48M 72.48%	-70.29M 69.46%	-119.33M 69.77%	-191M 60.06%	-251M 31.41%	-363.90M 44.98%
income tax expense	-87.41K -	604.52K 791.60%	2.38M 293.55%	-8.16M 443.00%	-7.55M 7.53%	-7.80M 3.37%	20.90M 367.95%	900K 95.69%
net income	-14.35M -	-24.05M 67.58%	-41.48M 72.48%	-62.13M 49.79%	-111.79M 79.92%	-183.20M 63.88%	-271.90M 48.42%	-367.30M 35.09%
weighted average shs out	17.88M -	20.73M 15.95%	9.42M 54.55%	32.93M 249.45%	39.53M 20.06%	50M 26.47%	53.20M 6.40%	55.50M 4.32%
weighted average shs out dil	17.88M -	20.73M 15.95%	9.42M 54.55%	32.93M 249.45%	39.53M 20.06%	50M 26.47%	53.20M 6.40%	55.50M 4.32%
eps	-0.80 -	-1.16 45.00%	-4.40 279.31%	-1.89 57.05%	-2.83 49.74%	-3.66 29.33%	-5.11 39.62%	-6.62 29.55%
epsdiluted	-0.80 -	-1.16 45.00%	-4.40 279.31%	-1.89 57.05%	-2.83 49.74%	-3.66 29.33%	-5.11 39.62%	-6.62 29.55%

COM:ARVINAS

Arvinas, Inc.

Last Close

25.11

22/11 21:00

Market Cap

1.80B

Beta: -

Volume Today

1.04M

Avg: -

Preview